Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrelimab (JNJ-63723283) Monotherapy or with Erdafitinib in Advanced Solid Cancers
NCT03547037Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of cetrelimab in malignant solid tumor (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity up to 6 weeks and Severity of Dose Limiting Toxicity up to 6 weeks. Started Aug 2018; status: completed.
02
Drugs
cetrelimab
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03547037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547037.